Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8th 2016
Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).